Quantcast

Latest Bronchodilator Stories

2014-06-19 08:28:42

BURLINGTON, ON, June 19, 2014 /CNW/ - Results from a Phase III 52 week study, show tiotropium (delivered via Respimat(®)*)5µg, a once-daily long-acting anticholinergic bronchodilator, is efficacious and well-tolerated as an add-on treatment in Japanese adults with moderate to severe symptomatic asthma, despite treatment with inhaled corticosteroids (ICS) with or without long-acting beta-2 agonist (LABA). "Even with available treatments, the extent to which patients' asthma is controlled...

2014-04-30 20:23:46

LONDON, April 30, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Incruse(TM) Ellipta(®) (umeclidinium) as an anticholinergic indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Umeclidinium is GSK's first once-daily anticholinergic, a type of...

2014-04-24 12:28:48

Each of the Emerging LABA/LAMA Fixed-Dose Combinations Has Advantages Over Current Therapies on Efficacy Measures, According to Findings from Decision Resources Group BURLINGTON, Mass., April 24, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. and European pulmonologists agree that a therapy offering a greater reduction in exacerbations is among the areas of greatest opportunity for chronic obstructive pulmonary disease (COPD) treatments. The majority of surveyed U.S....

2014-04-23 23:04:20

New research report “COPD Drug Market Opportunity & Clinical Pipeline Analysis” worked out by Kuick Research is now available at MarketPublishers.com. According to the study, the world COPD market is predicted to grow at a CAGR of nearly 8% and reach USD 17.5 billion by 2018. London, UK (PRWEB) April 23, 2014 Around 1 billion people across the globe suffer from pulmonary or respiratory diseases. Within the respiratory therapeutic domain, chronic obstructive pulmonary disease...

2014-01-13 16:25:12

-- Ultibro(TM) Breezhaler®1(QVA149), a long-term once-daily dual bronchodilator, received Health Canada approval on December 23rd 2013 for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema -- Pivotal Phase III IGNITE data showed QVA149 significantly improved lung function and patient-reported outcomes including...

2013-12-12 10:33:22

A new guideline has provided an updated definition of severe asthma along with new recommendations for treating the condition. Produced by a joint task force of the European Respiratory Society and the American Thoracic Society, the guideline is published online today (12 December 2013) in the European Respiratory Journal. Although severe asthma is estimated to account for less than 10% of all asthmatics, these patients have the greatest burden and require a disproportionate amount of...

2013-09-25 23:35:56

Avail is conducting a 24-week study to evaluate the effect of a once-daily experimental inhalation therapy on arterial stiffness compared to a placebo and another drug in subjects with Chronic Obstructive Pulmonary Disease (COPD). DeLand, Florida (PRWEB) September 25, 2013 *To see if you qualify for this COPD Clinical Trial in Florida, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. There is no cost to participate, no...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related